UBS/CALL/ELI LILLY & CO/700.001/0.01/20.09.24 | Real-time Bid/Ask 03:52:47 29/05/2024 pm IST | ||
| 1.19 CHF / 1.21 CHF | -4.76% |
|
| Current month | +55.56% | ||
| 1 month | +55.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 1.26 | -0.79% |
| 23/24/23 | 1.27 | +6.72% |
| 22/24/22 | 1.19 | -1.65% |
Delayed Quote Swiss Exchange
Last update May 24, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYC7U | |
| ISIN | CH1286555979 |
| Date issued | 18/09/2023 |
| Strike | 700 $ |
| Maturity | 20/09/2024 (114 Days) |
| Parity | 100 : 1 |
| Emission price | 0.26 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.28 CHF |
|---|---|
| Lowest since issue | 0.17 CHF |
| Spread | 0.02 CHF |
| Spread % | 1.65% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
- Stock Market
- Warrants
- LLYC7U Warrant
